Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P

Neurochemistry International

Volumn 55, Issue 4, 2009, Pages 214-218

  Koopman, Karen ^b,e   Le Bastard, Nathalie ^a   Martin, Jean Jacques ^a   Nagels, Guy ^b,f   De Deyn, Peter P ^a,b,d   Engelborghs, Sebastiaan ^a,b,c,d  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b MIDDELHEIM HOSPITAL   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d Hogeschool Antwerpen   (Belgium)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f National Multiple Sclerosis Center   (Belgium)

Author keywords

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Dementia; Hyperphosphorylated tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; THREONINE;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; AUTOPSY; BIOLOGICAL MARKERS; BRAIN; CATALYTIC DOMAIN; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; NEUROFIBRILLARY TANGLES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; SENILE PLAQUES; SENSITIVITY AND SPECIFICITY; TAU PROTEINS; THREONINE;

EID: 67349214609     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.02.017     Document Type: Article

References (26)

1. Andreasen N., and Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin. Neurol. Neurosurg. 107 (2005) 165-173
2. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., and Blennow K. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 58 (2001) 373-379
3. Blennow K., and Vanmechelen E. CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Res. Bull. 61 (2003) 235-242
4. Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., and Del T.K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112 (2006) 389-404
5. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82 (1991) 239-259
6. Diniz B.S., Pinto Júnior J.A., and Forlenza O.V. Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World J. Biol. Psychiatry 9 (2008) 172-182
7. Engelborghs S., Maertens K., Vloeberghs E., Aerts T., Somers N., Mariën P., and De Deyn P.P. Neuropsychological and behavioural correlates of CSF biomarkers in dementia. Neurochem. Int. 48 (2006) 286-295
8. Engelborghs S., Sleegers K., Cras P., Brouwers N., Serneels S., De Leenheir E., Martin J.J., Vanmechelen E., Van Broeckhoven C., and De Deyn P.P. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. Brain 130 (2007) 2320-2326
9. Engelborghs S., De Vreese K., Van de Casteele T., Vanderstichele H., Van Everbroeck B., Cras P., Martin J.J., Vanmechelen E., and De Deyn P.P. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol. Aging 29 (2008) 1143-1159
10. Frankfort S.V., Tulner L.R., van Campen J.P., Verbeek M.M., Jansen R.W., and Beijnen J.H. Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. Curr. Clin. Pharamacol. 3 (2008) 123-131
11. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D., Thomas R., Kholodenko D., Schenk D., Lieberburg I., Miller B., Green R., Basherad R., Kertiles L., Boss M.A., and Seubert P. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 55 (1998) 937-945
12. Hampel H., Buerger K., Zinkowski R., Teipel S.J., Goernitz A., Andreasen N., Sjoegren M., DeBernardis J., Kerkman D., Ishiguro K., Ohno H., Vanmechelen E., Vanderstichele H., McCulloch C., Moller H.J., Davies P., and Blennow K. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry 61 (2004) 95-102
13. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H.C., Riemenschneider M., De Deyn P.P., Bancher C., Cras P., Wiltfang J., Mehta P.D., Iqbal K., Pottel H., Vanmechelen E., and Vanderstichele H. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52 (1999) 1555-1562
14. Jackson M., and Lowe J. The new neuropathology of degenerative frontotemporal dementias. Acta Neuropathol. 91 (1996) 127-134
15. Jellinger K.A. The neuropathological diagnosis of Alzheimer disease. J. Neural Transm. Suppl. 53 (1998) 97-118
16. Knopman, D.S., Dekosky, S.T., Cummings, J.L., Chui, H., Corey-Bloom, J., Relkin, N., Small, G.W., Miller, B., Stevens, J.C., 2001. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1143-1153.
17. Kosaka K., Tsuchiya K., and Yoshimura M. Lewy body disease with and without dementia: a clinicopathological study of 35 cases. Clin. Neuropathol. 7 (1988) 299-305
18. Lewczuk P., Beck G., Ganslandt O., Esselmann H., Deisenhammer F., Regeniter A., Petereit H.F., Tumani H., Gerritzen A., Oschmann P., Schröder J., Schönknecht P., Zimmermann K., Hampel H., Bürger K., Otto M., Haustein S., Herzog K., Dannenberg R., Wurster U., Bibl M., Maler J.M., Reubach U., Kornhuber J., and Wiltfang J. International quality control survey of neurochemical dementia diagnostics. Neurosci. Lett. 409 (2006) 1-4
19. Markesbery W.R. Neuropathology of Dementing Disorders (1998), Arnold, London
20. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
21. Schoonenboom N.S., Pijnenburg Y.A., Mulder C., Rosso S.M., Van Elk E.J., Van Kamp G.J., Van Swieten J.C., and Scheltens P. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62 (2004) 1580-1584
22. Shoji M., Kanai M., Matsubara E., Ikeda M., Harigaya Y., Okamoto K., and Hirai S. Taps to Alzheimer's patients: a continuous Japanese study of cerebrospinal fluid biomarkers. Ann. Neurol. 48 (2000) 402
23. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., Bergeson J., Manetti G.J., Zimmermann M., Tang B., Bartko J.J., and Cohen R.M. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. J. Am. Med. Assoc. 289 (2003) 2094-2103
24. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association of the National Institute on Aging Working Group, 1998. Consensus Report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease. Neurobiol. Aging 19, 109-116.
25. Vanderstichele H., De V.K., Blennow K., Andreasen N., Sindic C., Ivanoiu A., Hampel H., Burger K., Parnetti L., Lanari A., Padovani A., DiLuca M., Blaser M., Olsson A.O., Pottel H., Hulstaert F., and Vanmechelen E. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin. Chem. Lab. Med. 44 (2006) 1472-1480
26. Welge V., Fiege O., Lewczuk P., Mollenhauer B., Esselmann H., Klafki H.W., Wolf S., Trenkwalder C., Otto M., Kornhuber J., Wiltfang J., and Bibl M. Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer's disease. J. Neural Transm. 116 (2009) 203-212